$4.25 Million in Sales Expected for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) This Quarter

Analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to announce sales of $4.25 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $7.00 million. Adaptimmune Therapeutics posted sales of $9.04 million in the same quarter last year, which suggests a negative year over year growth rate of 53%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Adaptimmune Therapeutics will report full year sales of $15.17 million for the current financial year, with estimates ranging from $4.50 million to $21.00 million. For the next year, analysts forecast that the firm will post sales of $17.75 million, with estimates ranging from $1.00 million to $36.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%.

A number of research firms have recently weighed in on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 11th. Roth Capital began coverage on shares of Adaptimmune Therapeutics in a research note on Friday, May 31st. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Leerink Swann downgraded shares of Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price target on the stock. in a research note on Tuesday, May 7th. Finally, ValuEngine downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.81.

NASDAQ ADAP opened at $4.02 on Friday. Adaptimmune Therapeutics has a 1-year low of $3.20 and a 1-year high of $14.54. The company has a debt-to-equity ratio of 0.12, a current ratio of 8.55 and a quick ratio of 8.55. The firm has a market capitalization of $413.53 million, a P/E ratio of -4.19 and a beta of 1.56. The stock has a fifty day moving average of $3.69.

A number of large investors have recently modified their holdings of the stock. Baillie Gifford & Co. boosted its holdings in Adaptimmune Therapeutics by 3.8% in the first quarter. Baillie Gifford & Co. now owns 3,839,190 shares of the biotechnology company’s stock worth $16,508,000 after purchasing an additional 139,669 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in Adaptimmune Therapeutics by 102.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,350,655 shares of the biotechnology company’s stock worth $7,766,000 after purchasing an additional 684,062 shares in the last quarter. BlackRock Inc. boosted its holdings in Adaptimmune Therapeutics by 10.4% in the fourth quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock worth $4,924,000 after purchasing an additional 81,010 shares in the last quarter. Foresite Capital Management II LLC boosted its holdings in Adaptimmune Therapeutics by 40.0% in the fourth quarter. Foresite Capital Management II LLC now owns 700,000 shares of the biotechnology company’s stock worth $4,025,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Rathbone Brothers plc boosted its holdings in Adaptimmune Therapeutics by 27.9% in the first quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock worth $1,229,000 after purchasing an additional 62,292 shares in the last quarter. Hedge funds and other institutional investors own 66.30% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Read More: Why are percentage decliners important?

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.